New aspects in the diagnosis and treatment of Cushing disease.
Cushing disease, which is caused by the excessive production of ACTH, is a rare and complex endocrine disorder that still represents a major challenge for the physician in terms of accurate diagnosis and efficient treatment. Diagnosing Cushing syndrome and its etiology is an elaborate procedure and no single test is sensitive and specific enough to provide sufficient accuracy. Therefore, an ordered cascade of tests is necessary recommended by a consensus statement in 2002. The proposed diagnostic algorithm will be summarized in the following section. In the absence of efficient drug therapy, transsphenoidal resection of the pituitary adenoma is the treatment of choice for the reduction of ACTH secretion. However, not all patients can be cured by surgery. In the present article, we examine recent studies that have investigated the therapeutic potential of new generations of drugs for the treatment of Cushing disease such as cabergoline and SOM230. The role of nuclear receptors: retinoic acid receptors and peroxisome proliferator-activated receptor-gamma as new approaches for treating pituitary tumors is also discussed.
Labeur
M
M
Max-Planck-Institute of Psychiatry, Munich, Germany.
Theodoropoulou
M
M
Sievers
C
C
Paez-Pereda
M
M
Castillo
V
V
Arzt
E
E
Stalla
G K
GK
D000465:Algorithms; D000818:Animals; D003937:Diagnosis, Differential; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D047495:PPAR gamma / Q000627:therapeutic use; D047748:Pituitary ACTH Hypersecretion / Q000175:diagnosis* / Q000628:therapy*; D013004:Somatostatin / Q000031:analogs & derivatives; D014212:Tretinoin / Q000627:therapeutic use
D018491:Dopamine Agonists; D008024:Ligands; D047495:PPAR gamma; D013004:Somatostatin; D014212:Tretinoin